Anti-Cancer Combination Treatment and Kit-of-Parts
AssigneeGlycanova AS
InventorBjørn Kristiansen
Life of this patent
Estimating the term…
Abstract
In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime.
Claims195
A pharmaceutical kit of parts comprising
- a) an anti-cancer medicament,
- b) a Basidiomycete bioactive agent in solid or liquid form, and, optionally
- c) instructions for a dosing regime.
The kit according to any of the preceding claims, wherein the Agaricus bioactive agent comprises or consists of an optionally glycosylated peptide.
The kit according to any of the preceding claims, wherein the bioactive agent stimulates the immune system of an animal or a human when administered to said animal or human in a pharmaceutically active amount.
The kit according to any of the preceding claims, wherein the bioactive agent is precipitated by alcohol precipitation.
The kit according to any of the preceding claims, wherein the bioactive agent is precipitated by ultracentrifugation.
The kit according to any of the preceding claims, wherein the bioactive agent is size fractionated prior to precipitation or centrifugation.
The kit according to any of the preceding claims, wherein the bioactive agent is further purified by one or more steps involving washing, desalting, size fractionation, and affinity chromatography, such as ion-exchange chromatography.
The kit according to any of the preceding claims, wherein the bioactive agent is further purified by washing and ion-exchange chromatography.
The kit according to any of the preceding claims, wherein the precipitated immune stimulating agent is further purified by size exclusion chromatography or gel filtration.
The kit according to any of the preceding claims, wherein the bioactive agent is extracellularly located and can be isolated from the liquid growth medium and optionally is also produced intracellularly in said Basidiomycete sp.
The kit according to ally of the preceding claims, wherein the bioactive agent is extracellularly located and immunologically distinct from an intracellularly produced bioactive variant of the agent having the same activity.
The kit according to any of the preceding claims, wherein the liquid growth medium comprises one or more of malt extract, yeast extract, peptone, glucose, sucrose, salts providing phosphate, magnesium and potassium, corn-steep liquor and vitamins, such as thiamine.
The kit according to any of the preceding claims, wherein the Basidiomycete sp. is grown in a liquid growth medium comprising malt extract, yeast extract, peptone, and glucose.
The kit according to any of the preceding claims, wherein the Basidiomycete sp. is grown in a liquid growth medium which is agitated and supplied with an oxygen source.
The kit according to any of the preceding claims, wherein the Basidiomycete sp. is grown at a temperature in the range of from 23° C. to 32° C.
The kit according to any of the preceding claims, wherein Basidiomycete sp. mycelium is removed from the liquid growth medium prior to the isolation of the immune stimulating agent.
The kit according to any of the preceding claims, wherein the fungal mycelium is removed from the initial culture by filtration or centrifugation.
The kit according to any of the preceding claims, wherein said anti-cancer medicament is suitable for administration simultaneously with the administration of the bioactive agent, such as in a co-formulation.
The kit according to any of the preceding claims, wherein said anti-cancer medicament and the bioactive agent are suitable for sequential administration, in any order, such as first the bioactive agent and then the anti-cancer medicament.
The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for subcutaneous administrationn.
The kit according to any of the preceding claims, wherein said medicament and/or agent are administered nasally.
The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for administration via the pulmonary route, such as via aerosol administration.
The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for administration via the parenteral route.
The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for oral administration.
The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for topical administration.
The kit according to any of the preceding claims, wherein said medicament and/or agent are co-formulated in a composition.
Use of an anti-cancer medicament and an Basidiomycete sp. bioactive agent for the manufacture of a kit of parts suitable for administration to an individual in need thereof.
A method for enhancing the therapeutic effect of an anti-cancer drug, comprising co-administering with said anti-cancer drug a Basidiomycete sp. bioactive agent.
Dependencies are inferred from the claim text.